Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
about
Immune response to vaccine adjuvants during the first year of lifeA universal polysaccharide conjugated vaccine against O111 E. coli.Polysaccharide-specific B cell responses to vaccination in humansPneumococcal vaccination: what have we learnt so far and what can we expect in the future?Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Consensus Recommendation for India and Bangladesh for the Use of Pneumococcal Vaccine in Mass Gatherings with Special Reference to Hajj Pilgrims.The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.Listeria monocytogenes: a promising vehicle for neonatal vaccination.The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Treatment of bacterial meningitis: an update.Effect of vaccine-elicited antibodies on colonization of Neisseria meningitidis serogroup B and C strains in a human bronchial epithelial cell culture model.Strategies to develop vaccines of pediatric interest.Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccineAge and risk factors influence the microbial aetiology of bloodstream infection in children.Memory B cell compartment constitution and susceptibility to recurrent lower respiratory tract infections in young children.Vaccines in clinical trials: infectious disease.Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.A Three Component Synthetic Vaccine Containing a β-Mannan T-Cell Peptide Epitope and a β-Glucan Dendritic Cell Ligand
P2860
Q27016633-E201FEA6-1315-4382-ADD9-EC3A2EDF5104Q33419199-91177192-E4C0-4B95-84E4-85280EC59173Q33577958-F9FB1980-A2D2-4E29-A62F-957AD44E3BD4Q34798448-0279BF3C-B68B-4DF0-890C-71E67A98A8CDQ35855954-7EE19D12-D17A-45FD-8B4A-E1D000E71741Q35867061-B45374C9-8F82-4AF8-B9CA-60654718EA70Q36220236-BD827974-4D4E-4E92-BEDF-E38E592E3DC9Q36646787-DAD49958-F878-444C-AF2E-DB03111F4B29Q36977730-F42B3EA1-172E-4AD6-B519-1A578E0F876FQ37037419-C09BDA56-5041-43A0-AB55-5829FA71750AQ38044024-327684E5-A716-4561-B928-4E48CA2FE9D5Q38631739-3B507644-7C40-42DC-9E7D-3C81C9127DDBQ38819027-C6BF1539-4BC0-4059-A356-1948217F948BQ41512011-5D519976-D93B-4F05-89A6-0A47020EF663Q42287929-F0DFBCEE-298A-4175-BCF0-AA66FFEAAC27Q44220499-051801D5-ED44-43D2-BAF1-E3ED8160E202Q47980661-3423ADF6-1BF3-4949-BD9A-DA9727B73F3BQ52365761-BF80041C-AF97-4DE4-8B49-90CBA9234848Q53762383-F02658A9-D586-4F42-9635-C4BCBD482708Q58692952-C9924CA8-BF6B-430B-AC5E-379909AC2582
P2860
Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term protection after imm ...... conjugate vaccines in infancy.
@en
Long-term protection after imm ...... conjugate vaccines in infancy.
@nl
type
label
Long-term protection after imm ...... conjugate vaccines in infancy.
@en
Long-term protection after imm ...... conjugate vaccines in infancy.
@nl
prefLabel
Long-term protection after imm ...... conjugate vaccines in infancy.
@en
Long-term protection after imm ...... conjugate vaccines in infancy.
@nl
P2860
P356
P1476
Long-term protection after imm ...... conjugate vaccines in infancy.
@en
P2093
Andrew J Pollard
Geraldine Blanchard-Rohner
P2860
P304
P356
10.1586/ERV.11.14
P577
2011-05-01T00:00:00Z